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Abstract
Background: Urinary tract infection (UTI) is one of the most common diagnoses in girls and women, and to a lesser
extent in boys and men younger than 50 years. Escherichia coli, followed by Klebsiella spp. and Proteus spp., cause
75-90% of all infections. Infection of the urinary tract is identified by growth of a significant number of a single species
in the urine, in the presence of symptoms. Urinary culture is an accurate diagnostic method but takes several hours or
days to be carried out. Metabolomics analysis aims to identify biomarkers that are capable of speeding up diagnosis.
Methods: Urine samples from 51 patients with a prior diagnosis of Escherichia coli-associated UTI, from 21 patients with
UTI caused by other pathogens (bacteria and fungi), and from 61 healthy controls were analyzed. The 1H-NMR spectra
were acquired and processed. Multivariate statistical models were applied and their performance was validated using
permutation test and ROC curve.
Results: Orthogonal Partial Least Squares-discriminant Analysis (OPLS-DA) showed good separation (R2Y = 0.76,
Q2=0.45, p < 0.001) between UTI caused by Escherichia coli and healthy controls. Acetate and trimethylamine were
identified as discriminant metabolites. The concentrations of both metabolites were calculated and used to build the
ROC curves. The discriminant metabolites identified were also evaluated in urine samples from patients with other
pathogens infections to test their specificity.
Conclusions: Acetate and trimethylamine were identified as optimal candidates for biomarkers for UTI diagnosis.
The conclusions support the possibility of a fast diagnostic test for Escherichia coli-associated UTI using acetate and
trimethylamine concentrations.
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Background
Uncomplicated urinary tract infection (UTI) is one of the
most common diagnoses especially in young women who
are sexually active, and although less frequent still reason-
ably common in older women, pregnant women and men
[1, 2]. Uncomplicated cystitis and pyelonephritis are
mainly caused by Escherichia coli (75% -95%) and possibly
by other species of Enterobacteriaceae (such as Proteus
mirabilis and Klebsiella pneumoniae) and Staphylococcus
saprophyticus [3]. Other gram-negative and gram-positive
species are rarely isolated in uncomplicated UTIs. Signs
and symptoms of acute uncomplicated UTI include dys-
uria, urinary frequency or urinary urgency, loin pain, and
eventually hematuria. The occurrence of other symptoms,
such as vaginitis and urethritis suggests alternative diagno-
ses. The diagnosis of UTI is generally a clinical diagnosis
based on symptoms and signs, and urine culture is usually
not required to manage uncomplicated infections [1]. In
fact, recent expert guidelines [4] state that for women
without a history of a laboratory-confirmed UTI, a visit in
a clinic, or ambulatory care facility for urinalysis or dip-
stick testing is appropriate. However, it is recommended
that in symptomatic patients a negative dipstick result
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should be confirmed by a urine culture, urinalysis, or both
[1, 4]. Urine culture is the gold standard for the microbio-
logical diagnosis of UTI, and it is routinely used in most
clinical laboratories [5]. As well, the method is labour in-
tensive and time-consuming, and the turnaround time to
obtain culture results is often exceeding the time re-
quested to start the antimicrobial treatment. Moreover,
only half of the symptomatic women have a UTI if the
definition of infection is more than 105 colony-forming
units (CFU)/mL. Nevertheless, both urinalysis and culture
are not able to predict clinical outcome in most women
with clinical signs of infection, and recent evidence-based
guidelines suggest that treating adult symptomatic women
without laboratory testing does not increase adverse out-
comes [6, 7]. Accordingly, given the cost and time con-
strains routine urine culture should be avoided to manage
most uncomplicated UTI. Finally, prescriptions for UTI
treatment have a significant impact on total antibiotic
consumption and are associated both with an increase in
expense for healthcare and with the spread of antibiotic
resistance. Clearly, better and rapid diagnosis of UTI
might prevent patients from being unnecessarily treated
[4]. In the light of these recommendations, there is a need
to develop a simpler, faster and cheaper tool to predict the
causative organisms for bacterial UTI, or at least those
suspected as the most likely source of UTI. For these rea-
sons, any improvement in the diagnostic process of UTI
would greatly impact future healthcare.
Recently, the availability of new technologies such as
identification by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-
TOF) and the development of automated solutions
designed for microbiology have had a positive impact on
patient management and hospital costs, increasing prod-
uctivity and quality, and reducing turnaround time and
laboratory costs [8, 9]. Furthermore, application of high-
resolution nuclear magnetic resonance spectroscopy
(NMR) and mass spectrometry (MS), ultra-performance
liquid chromatography, coupled with analytical and bio-
informatics techniques, has enabled the metabolomics
profiles of a number of diseases to be comprehensively
investigated [10]. In particular, in the recent years 1H-
NMR spectrometry has been used in the diagnosis of
bacterial UTI, reaching an accuracy of nearly 99.5%
using a multivariable prediction model. With this ap-
proach, a panel of biomarkers could act as indicators of
UTI, thus providing a feasible method for diagnosis
[11–16]. Here we confirm that NMR-based urinalysis is
a useful and rapid method for the etiological diagnosis
of E. coli-associated UTI that could be properly trans-
lated for clinical practice.
Results
Based on the urine culture results, 51 patients with E.
coli-associated UTI (E. coli-pos), 21 patients with non-E.
coli UTI, and 61 healthy controls (CTRLs) were selected
for the metabolomics analysis. Clinical and demographic
characteristics of the patients and the healthy subjects
are summarized in Table 1. Amongst the 72 patients
positive for microbial infection, only 72% were positive
for nitrite after dipstick urinalysis. On the other hand,
about 93% resulted positive for the nonspecific inflam-
mation marker leukocyte esterase. All urine samples
underwent NMR analysis. A representative 1H NMR
spectrum of urine obtained from E. coli-pos sample is
reported in Additional file 1: Figure S1.
Table 1 Characteristics of the 133 subjects of the study
Characteristics UTI patients (E.coli) UTI patients (other pathogens) Controls
N = 51 N = 21 N = 61
Age, median ± SD 60 ± 20 73 ± 13.98 52 ± 18
Male, n (%) 9 (17.6) 8 (38.1) 26 (42.6)
Female, n (%) 42 (82.4) 13 (61.9) 35 (57.4)
Smoking, n (%) 12 (23.5) missing values 18 (29.5)
Co-morbidity, n (%)
Diabetes mellitus 3 (5.9) 5 (23.8) 4 (6.5)
BPCO 2 (3.9) 0 (−) 0 (−)
Malignancy 1 (1.9) 2 (9.5) 1 (1.6)
Arthritis 4 (7.8) 0 (−) 3 (4.9)
Hearth failure 0 (−) 1 (4.8) 0 (−)
Immunodeficiency 0 (−) 1 (4.8) 0 (−)
Urinary dipstick results
Nitrite 37 (72.5) 13 (61.9) 1 (1.6)
Leukocyte esterase 49 (96.0) 18 (85.7) 3 (4.9)
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In order to perform the multivariate statistical analysis,
the data from E. coli-pos and CTRLs samples were split
into training set and validation set. Training set was com-
posed of 72 samples (31 E. coli-pos + 41 CTRLs) and the
validation set of 40 samples. The multivariate statistical
analysis was carried out using binned bucketed data.
To generate an overview of the dataset variation, a
Principal Components Analysis (PCA) was first per-
formed based on the normalized NMR spectral data ob-
tained from urine samples. In order to get a better
discrimination between the groups, orthogonal partial
least square-discriminant analysis (OPLS-DA) was ap-
plied in our study. The OPLS-DA showed a clear separ-
ation of samples into two distinct groups, indicating that
the E. coli-pos and CTRLs samples had a significant dif-
ferent metabolic profile. Score plots using the first two
PCs were used to present a 2D representation of
variations among the spectra (Fig. 1a).
The OPLS-DA model was established with one-
predictive and one-orthogonal components, and
showed good values of R2Y (0.76) and Q2 (0.45) and a
p value < 0.001. Then, in order to test the validity of the
OPLS-DA model, a permutation test (200 times) on the
corresponding PLS-DA model was performed by using
the same number of components (Additional file 2:
Figure S2).
The R2 and Q2 values derived from the permuted
data were lower than the original values and the regres-
sion of Q2 line intersected at below zero, indicating the
validation of the PLS-DA model (Q2 of - 0.131). By
analyzing the coefficient loading plot color-based be-
tween the Controls and E. coli-associated UTI we se-
lected regions of the spectra with a key role on the
OPLS-DA (Fig. 1b). The validation set was then used.
The classification of an external validation dataset using
the model-parameters based on the training set pro-
vides information about the generalizability of the
model. The predicted value of Y variable based on
OPLS-DA was calculated for all prediction set and used
as classifier. Receiver operating characteristic (ROC)
Fig. 1 a) Distribution of E. coli-associated UTI and healthy controls obtained with a OPLS-DA model. Controls (open circle), E. coli-associated UTI
(full circle). b). Color-coded coefficient loadings plots between the Controls and E. coli-associated UTI
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curve analysis was applied to provide a measure of
clinical utility. The area under the ROC curve (AUC)
calculated using the Y-predicted value was 0.79 (95% CI
0.61-0.98) (Fig. 2a).
Using the ChenomX software, the discriminant metab-
olites were identified and quantified. This method com-
pares the integral of a known reference signal
(trimethylsilyl propanoic acid, TSP), with signals derived
from a documented database of about 350 compounds
in order to determine concentrations relative to the ref-
erence signal. The univariate statistics were calculated
using the Mann Whitney U test, with each metabolite
concentration normalized to the creatinine concentra-
tion. The discriminant metabolites, their chemical shifts
and the p-values are listed in Table 2. Acetate, Ac, and
trimethylamine, TMA, were shown to be the most dis-
criminatory metabolites. Box plots of relative concentra-
tions for both metabolites are shown in Fig. 3, indicating
the diversity of individual metabolites among different
groups. The ROC curve build using both metabolites
gave an AUC of 0.938 (95% CI 0.86-1.02) (Fig. 2b).
The concentrations of these metabolites were also
evaluated in urine samples from patients with infections
with other pathogens to test the specificity of their de-
tection. These metabolites were used as classifiers and
the area under the ROC curve was evaluated. The ROC
analysis results are shown in Table 3. The AUC from
ROC curve build comparing E. coli-pos vs. CTRLs sam-
ples was 0.92 (95% CI 0.81-1.0) for acetate and 0.89
(95% CI 0.79-0.99) for TMA, and 0.94 (% CI 0.86-1.0)
combining both metabolites, respectively. This indicates
that ROC curve by single metabolite concentrations are
not performing as well as using them together. The use
of both acetate and trimethylamine concentrations
shows almost 100% sensitivity and 100% specificity. The
comparison between E. coli-pos samples and group “All”
(CTRLs + non-E. coli) shows an AUC of 0.89 (95% CI
0.80-0.98) for Ac, 0.80 (95% CI 0.67-0.94) for TMA, and
0.89 (95% CI 0.80-0.99) using both, respectively. The
results get worse, in terms of AUC, when comparing E.
coli-pos and non-E. coli samples.
Discussion
Urinary tract infections are a common problem in adults
that frequently need prescriptions of laboratory tests and
Fig. 2 ROC Curve built using (a) Y predicted (OPSL-DA) and (b) Acetate and trimethylamine concentrations derived from patients with E. coli-
associated UTI and healthy controls
Table 2 List of discriminant metabolites based on the
discriminant analysis (OPLS-DA) of Controls vs E. coli-pos
Metabolite Chemical Shift (ppm) p value
Acetate 1.93 <0.0001
Trimethilamine 2.89 <0.0001
Trimethilamine N-Oxide 3.28 NS
Citrate 2.54, 2.66 NS
Hippurate 3.97, 7.84, 7.55, 7.64 NS
Glycine 3.55 NS
P-values, derived by the Mann Withney univariate analysis, were calculated
using metabolites concentrations normalized to the creatinine concentration
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use of antibiotics. On the other hand, the diagnosis of
UTI is mainly a clinical diagnosis, and is primarily based
on symptoms and signs and should not rely exclusively
on laboratory tests that detect the presence of bacteria
and/or white cells in urine, but diagnosis based only on
symptoms risks overestimating real UTI [17]. Dipstick
urinalysis provides some support with leukocyte esterase
and nitrite information. They can be nonspecific since
the leukocyte esterase is a marker of granulocytes and
not sensitive as not all urinary pathogens produce ni-
trite, sensitivity of nitrite being between 37 and 59%
[18]. In our study, in fact, the two parameters showed
better performances, though they did not reach suffi-
cient levels of analytical sensitivity, as expected.
Most human diseases have characteristic modifica-
tions in the metabolite profiles of fluids prior and dur-
ing the development of clinical symptoms [19]. Thus,
metabolomics offers a unique tool to investigate the
complete set of small molecules derived from biochem-
ical changes due to ongoing disease. The identification
of these low-molecular-weight biomarkers will result in
the early and more accurate diagnosis, care of disease
and, as hopefully expected, in effective therapeutic
treatment [20–22]. NMR-based urinalysis for the
screening of UTI with high accuracy and reproducibil-
ity has previously been described. E. coli-associated
UTI, the most common scenario for all UTI, has
benefited from NMR analysis which provides a valuable
presumptive diagnosis for clinician judgment. Bacterial
metabolic end-products were invariably observed in
contaminated urine samples to date [23], and a set of
metabolites were investigated and proposed as marker
for bacterial UTI: in most studies, acetate and TMA
were indicated as ideal urine biomarker for bacterial
UTI and E. coli-associated UTI, in that their presence
can be attributed to the metabolic effect of bacterial
contamination of urine in the presence of ongoing dis-
ease [14, 15]. In particular, it is known that TMA pro-
duction is the result of integrated metabolism between
the host primary metabolome and microbes that reduce
trimethylamine N-oxide (TMAO) using the bacterial
trimethylamine N-oxide reductase in the urinary blad-
der, thus making TMA as a specific marker for bacterial
metabolic activity and a valuable marker of E. coli-asso-
ciated UTI [14, 15]. The use of TMA as a biomarker,
due to its origin, rules out a possible contamination as
a result of positive test. In this study, using a metabolo-
mics approach the urinary profile of UTI caused by the
gram-negative E. coli could be distinguished from that
of the healthy controls, and also from that caused by
other non-E. coli pathogens. We focused our study on
E. coli-positive patients in order to validate the metabo-
lomics approach in a well defined group of UTI caused
by the most frequently detected pathogen. Indeed, we
Fig. 3 Box-and-whisker of relative concentration of controls, E. coli-associated UTI and non-E. coli UTI urine samples. Statistical significance was
determined using the Mann-Whitney U test and a p-value <0.05 was considered statistically significant
Table 3 Comparison of ROC curves
Acetate Trimethylamine Ac + TMA
AUC 95% CI p value AUC 95% CI p value AUC 95% CI p value
E. coli-pos vs CTRLs 0.92 0.81-1.0 <0.0001 0.89 0.79-0.99 <0.0001 0.94 0.86-1.0 <0.0001
E. coli-pos vs non-E. coli 0.86 0.74-0.99 <0.0001 0.70 0.50-0.9 <0.0001 0.84 0.70-0.98 0.0003
E. coli-pos vs All 0.89 0.80-0.98 <0.0001 0.80 0.67-0.94 0.0002 0.89 0.80-0.99 <0.0001
Urine samples positive for E. coli infections were compared to CTRLs, non-E. coli and All patients
The area under the curve (AUC), the 95% confidence interval (CI), and the p values are reported. The ROC curves were built using Acetate and Trimethylamine,
individually, or combining both concentrations
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have shown that the method could be used to discrim-
inate the metabolomic profiles of UTI caused by other
pathogens, and further investigation will aim to validate
the specificity of the approach in different clinical con-
texts (especially in the intensive care units).
Acetate and trimethylamine concentrations appear
optimal candidates as biomarkers for E. coli-associated
UTI diagnosis in the clinical setting, and this can have
application in the selection of antibiotic treatment of the
patients.
In fact, the results suggest that NMR-based diagnosis
is a rapid, simple and safe test for the diagnosis of UTI
and enables the prescription of medication before the
microbiological diagnosis of UTI is confirmed. This ad-
vancement in clinical utility of non-cultured based diag-
nosis should be regarded as a paradigm shift in clinical
medicine and in microbiological diagnosis.
Conclusions
The study further confirms the value of NMR spectrom-
etry as a diagnostic tool for E. coli-associated UTI. The
method is validated for clinical purposes, easy to use, de-
livers reliable results with a rapid turn-around time, and
has a high sensitivity and specificity compared to routine
tests as urinalysis or dipstick testing. The discriminative
model enabled acetate and trimethylamine to correctly
provide information on bacterial contamination with E.
coli with a high predictive ability. Clinical application of
NMR spectroscopy has been previously assessed, and its
role as in vitro diagnostic test highlighted in a great var-
iety of diseases, including infections. One of the goal is
to restrict the use of empirical antibiotic treatments to
patients with UTI and to curtail the overuse of drugs
that increase the spread of antibiotic resistance and the
public health costs. A rapid, sensitive and cheap bio-
chemical test will in future well acceptable once it is
standardized and a precise cut-off level defined for the
identification and/or differentiation of specific UTI.
Methods
Patients
Urine samples, collected over the course of two years,
2013-2014, at Policlinico Universitario di Monserrato-
Cagliari (Italy) from a total of 133 subjects were analyzed:
51 patients with E. coli-associated UTI (E. coli-pos), 21 pa-
tients with UTI caused by other pathogens (Enterococcus
spp. = 6; Staphylococcus spp. = 4; Proteus spp. = 3;
Candida spp. = 8), and 61 healthy controls (CTRLs). All
samples had previously been collected for routine
mandatory diagnostic analysis from patients with acute
uncomplicated cystitis and manifesting symptoms of dys-
uria, urinary frequency, or urinary urgency, and in a few
cases, hematuria. Urine samples with negative or low col-
ony counts and without evidence of inflammatory disease
were used as the control group (Table 1). The following
parameters were registered for each patient: the collection
date, age, sex, identification of the bacteria strain associ-
ated with UTI, and the results of the antimicrobial suscep-
tibility test. Mid-stream urine samples were obtained
before starting antimicrobial therapy and analyzed using
standard microbiological methods. Samples were collected
and immediately aliquoted for the analysis after the
addition of sodium azide 0.1% (w/v) to stop bacteria
growth.
Microbiological assays
Samples for urine culture were analysed within one hour
of sampling; otherwise, they were stored at 4 °C and
processed until 24 h after collection. All samples were
inoculated in CLED agar as well as MacConkey agar and
Sabouraud dextrose agar (all from bioMérieux, Marcy-
l’Étoile, France), and were incubated under aerobic
conditions for 18-48 h at 35 °C. A positive culture was
defined as having a number of yielded colonies
≥103 CFU/ml when associated with clinically significant
signs in symptomatic patients and in light of the pa-
tient’s immunological status. Non-UTI controls were
samples with no microbial growth from subjects with a
negative history of UTI. The identification and anti-
microbial susceptibility of the isolated strains were
performed using automatized Vitek2 (bioMérieux,
Marcy-l’Étoile, France). The ATCC 25922 E. coli was
used for quality control and susceptibility defined in
accordance with EUCAST recommendations (http://
www.eucast.org/clinical_breakpoints/).
After sample collection, fractions of urine samples
were added with a solution of 0.1% sodium azide, then
centrifuged for 10 min at 4 °C at 12000 rpm to remove
whole cell debris and to avoid contaminants. The super-
natant was used for subsequent NMR analysis.
NMR spectroscopy analysis
For each sample 630 μl-aliquots were collected from the
supernatant and processed as previously described [24].
Samples were then transferred into a 5 mm NMR tube for
analysis. The 1H-NMR spectra were acquired using a
Varian Unity Inova 500 MHz spectrometer (Agilent Tech-
nologies, Santa Clara, CA, USA). The acquisition condi-
tions of the NMR spectra were the following: standard
temperature of 27 °C, 1D NOESY sequence with a 90°
pulse of 10.4 μs, acquisition time of 1.5 s and spectral
width of 6000 Hz. Free induction decay (FID) was ac-
quired 128 times to increase signal-to- noise ratio. FIDs
were weighted by an exponential function with a 0.5-Hz
line broadening factor prior to Fourier Transformation.
Finally, acquired spectra were phase and baseline
corrected (Version 7.1.2, Mestrelab Research S.L.).
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Statistical analysis
The 1H-NMR spectra were reduced to regions of 0.04 ppm
in the region 0.5–9.5 ppm, excluding urea and residual
water region. Total area for each spectum bin was normal-
ized to a constant sum of 100 to minimize the effects of
variable concentration among different samples [25].
The resulting dataset was then analyzed by using
SIMCA-P+ (Version 13.0, Umetrics, Umeå, Sweden).
Multivariate statistical models were validate as follows:
one-third of the samples were removed from the total
set and used as a validation set, and the rest of the sam-
ples were used for constructing the training set. The
class of samples in the validation dataset was then pre-
dicted based on the model built from the training set.
PCA was performed to get an overview of similarities/
differences between sample profiles and to detect pos-
sible outliers.
Additionally, PLS-DA was applied to maximize the sep-
aration between samples and to identify subsets (linear
combinations) of metabolic features associated with a spe-
cific sample class. OPLS-DA was applied to achieve a bet-
ter interpretation of PLS-DA models, as it removes
systematic variations from the data by placing them in or-
thogonal components and maximizing class separation in
the OPLS-DA component [26]. A permutation test was
performed using 200 permutations to check overfitting of
the PLS-DA model. Once the supervised model has been
estimated from the training set, the model can be used to
predict new observations. All observation of the
prediction-set can be predicted using the supervised
model calculating the predicted value of Y variable. The Y
predicted value could be used to build a classifier.
Six metabolites were identified as discriminant for
the separation between the E.coli-pos and CTRLs sam-
ples from the S-Plot line and, then, quantified using
ChenomX NMR Suite 7.1 (Chenomx Inc., Canada) [27].
Univariate statistical summaries and tests were per-
formed based on the creatinine-normalized concentra-
tions. The univariate statistics were calculated using the
Mann Withney U test to estimate the significance of
group differences. P-values of less than 0.05 were con-
sidered statistically significant.
The discriminant metabolites were also quantified in a
group of 21 urine samples with infections with other path-
ogens in order to test E. coli specificity. Each metabolite
was used to build a classifier to discriminate between E.
coli-pos versus CTRLs, E. coli-pos versus non-E. coli and
E. coli-pos versus “ALL” (CTRLs + non-E. coli).
The performance of the classifiers was assessed using
a ROC curve performed using GraphPad Prism version
7.00 (GraphPad Software, La Jolla California USA,
http://www.graphpad.com). ROC curves are summarized
in a single value, the area under the curve (AUC), that
ranges from 0 to 1.0. [28].
Additional files
Additional file 1: Figure S1. Representative 1H NMR spectra of E.Coli-
pos urine sample. 1 TSP; 2 lactate; 3 alanine; 4 acetate; 5 citrate; 6
dimethylamine; 7 trimethylamine; 8 creatinine; 9 histidine; 10 choline; 11
TMA N-Oxide; 12 taurine; 13 glycine; 14 urea; 15 phenylalanine;16
hippurate; 17 formate. (TIFF 156 kb)
Additional file 2: Figure S2. Statistical validation by permutation
analysis using 200 different model permutations. (TIFF 240 kb)
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Ac: Acetate; CFU: Colony-forming units; CTRLs: Healthy controls; FID: Free
induction decay; MS: Mass spectrometry; NMR: Nuclear magnetic resonance
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PCA: Principal components analysis; ROC: Receiver operating characteristic;
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